GH Research PLC (NASDAQ:GHRS) Receives $45.00 Consensus Target Price from Brokerages

by · The Markets Daily

GH Research PLC (NASDAQ:GHRS – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $45.00.

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC upped their price target on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Guggenheim boosted their target price on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of GH Research from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a report on Friday, July 17th.

Get Our Latest Report on GH Research

GH Research Price Performance

NASDAQ GHRS opened at $27.89 on Tuesday. The stock has a market capitalization of $1.91 billion, a PE ratio of -27.89 and a beta of 1.27. The business has a 50 day simple moving average of $28.23 and a two-hundred day simple moving average of $22.53. GH Research has a 1-year low of $12.04 and a 1-year high of $31.44.

GH Research (NASDAQ:GHRS – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. On average, analysts anticipate that GH Research will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. North Star Investment Management Corp. purchased a new stake in GH Research during the 1st quarter valued at $31,000. Royal Bank of Canada boosted its stake in GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after buying an additional 780 shares during the period. Squarepoint Ops LLC purchased a new position in GH Research during the second quarter worth $495,000. Renaissance Technologies LLC bought a new position in GH Research during the first quarter valued at $290,000. Finally, BIT Capital GmbH bought a new position in GH Research during the fourth quarter valued at $635,000. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland. Founded in 2018, the company focuses on developing novel therapies for psychiatric and neurological disorders, with an emphasis on treatments that may offer rapid effects.

Its lead program, GH001, is an inhaled formulation of mebufotenin, also known as 5-MeO-DMT, being studied for treatment-resistant depression. GH Research is also developing additional formulations and delivery approaches based on mebufotenin, including the GH002 program.

See Also